Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 7, 2023

Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days

GlobeNewswire March 28, 2023

Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023

GlobeNewswire March 23, 2023

Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 7, 2023

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 3, 2023

Chinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development Summit

GlobeNewswire February 28, 2023

Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

GlobeNewswire February 27, 2023

Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer

GlobeNewswire February 15, 2023

Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference

GlobeNewswire February 7, 2023

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 6, 2023

Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2023

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 22, 2022

Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 10, 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022

GlobeNewswire November 4, 2022

Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

GlobeNewswire November 3, 2022

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 2, 2022

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022

GlobeNewswire October 14, 2022

Chinook Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 1, 2022

Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 4, 2022